Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — Investor Presentation (April 2020)
27 slides from Armata Pharmaceuticals's investor presentation, Apr 28, 2020
Slide 1: Armata Pharmaceuticals corporate presentation, April 28, 2020
Todd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer April 28, 2020 NYSE American: ARMP
Slide 2: Forward-looking statements
2 I This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All
Slide 3: Investment Highlights: A Leader in Phage Therapeutics
3 I Two phage product candidates advanced through Pre - IND meeting with FDA • Expected IND filing for P. aeruginosa phage product candidate (AP - PA02) in 1H 2020 – Cystic fibrosis study supported by a $5 million Therapeutics Development Award through the CF Foundation • S. aureus phage product can
Slide 4: Armata Stands on Long History of Phage Development
4 I Armata Stands on Long History of Phage Development M&A Yields Leading Phage Company Biocontrol Ltd. Pre - IND S. aureus and P. aeruginosa phage SGI Asset Acquisition Synthetic phage platform ▪ Pseudomonas program ▪ Pharma partnered program GMP Facility 25 MDR Cases Under EIND Targeted Antimicrob
Slide 5: Armata's Capabilities and Operational Overview
5 I Armata’s Capabilities and Operational Overview Built for Product Development, Bench to Clinic Microbiology Phage Discovery Peptide Chemistry Leads Synthetic Biology Manufacturing & Quality Regulatory • Preclinical biology • Deep formulation expertise • Host cell engineering • Two targeted antimi
Slide 6: Pipeline
6 I Pipeline Phage libraries to address market expansion and new indications Pathogen / Indication Discovery Preclinical IND - Enabling CMC Phase 1b/2 Pseudomonas aeruginosa Cystic Fibrosis Lung Infections Staphylococcus aureus Bacteremia* Undisclosed Partnered AP - PA02 AP - SA02 * pending nondilut
Slide 7: Unmet Need in Antibiotic Resistant Infections
7 I Unmet Need in Antibiotic Resistant Infections Phages May Provide a Powerful Solution to an Urgent Public Health Threat Aug 2019 Xenleta (lefamulin)
Slide 8: Bacteriophages Infection Yields Progeny and Results in Bacterial Lysis
8 I Bacteriophages Infection Yields Progeny and Results in Bacterial Lysis Source: Prescott Harley Klein’s Microbiology, 7th Ed. • The most ubiquitous organisms on Earth • Natural predators of bacteria • Highly targeted • Prior history as therapeutic agent – Antibiotics displaced phage use • Drug -
Slide 9: Differentiating Attributes of Phage vs. Classic Antibiotics
9 I Highly specific bactericidal agents will not disrupt microbiome • Lowers risk of infection by Clostridium difficile and vancomycin - resistant enterococci No toxicities associated with chemical structures • Toxicities associated with antibiotics: kidney, bone marrow, hearing loss… Not an increme
Slide 10: Deadly Infections Successfully Treated With Phage
10 I Deadly Infections Successfully Treated With Phage Aortic Graft Pseudomonas Cystic Fibrosis Pseudomonas Cystic Fibrosis Pseudomonas Cystic Fibrosis NTM
Slide 11: Lead Indication: Pseudomonas aeruginosa Cystic Fibrosis Lung Infections
11 I Lead Indication Pseudomonas aeruginosa Cystic Fibrosis Lung Infections
Slide 12: Primary Clinical Inquiry: Cystic Fibrosis
12 I Primary Clinical Inquiry: Cystic Fibrosis • Chronic P. aeruginosa infections occur in 55% of CF patients by age 25 – Strongly associated with deteriorating lung function, frequent pulmonary exacerbations, increased mortality • Increased risk of death at 8 years in children with P. aeruginosa in
Slide 13: Integrated Approach Yields Robust Pseudomonas Phage Candidate
13 I In Vitro Killing Kinetics In Vivo Screening Manufacturing Feasibility Integrated Approach Yields Robust Pseud Phage Candidate surveillance Candidate Screening Initial phage pool Identify receptors Genomic analysis ID phage family Confirm lytic Prioritize on desired attributes: Broad host range
Slide 14: AP-PA02: Phage Product Tailored for Pa Respiratory Infections
14 I • Distinct phage families • Targets multiple different receptor classes • Cooperative/compatible • Broadly active against clinical isolates • Highly potent • Rapid test to drive early use in treatment paradigm • Highly sensitive, can identify colonized patients AP - PA02: Phage Product Tailored
Slide 15: AP-PA02: Product Development Status
15 I • cGMP laboratory designed for manufacturing and formulating sterile products – ISO - certified cleanrooms and closed system isolator – Registered with FDA; licensed by California Department of Public Health • Staffing – Independent Quality Unit – cGMP - trained manufacturing and facilities per
Slide 16: AP-PA02: Clinical Outline
16 I Near - term study Follow - on studies Future Opportunities AP - PA02: Clinical Outline Patient population: Medically stable chronically - infected CF patients Route of administration: Nebulized Goals: Safety and tolerability, pharmacokinetics, dose exploration Efficacy endpoints in CF populatio
Slide 17: Staphylococcus aureus Program
17 I Staphylococcus aureus Program
Slide 18: AP-SA02: Phage Product Targeting S. aureus
18 I • Host range coverage of >90% across clinical isolates tested • Robust potency against drug - resistant isolates, including MRSA, VISA, VRSA • Penetrates pre - existing biofilms • Maintains activity in presence of current standard anti - staphylococcal therapy AP - SA02: Phage Product Targeting
Slide 19: AP-SA02: Opportunities
19 I • First indication: S. auerus bacteremia – Subject of nondilutive funding opportunity – Phase 1b/2 dose escalation study • Administered intravenously as an adjunct to best available antibiotic therapy • Demonstrate safety and tolerability of multiple different dose levels • Determine optimal do
Slide 20: Corporate Summary
20 I Corporate Summary
Slide 21: Significant Opportunity to Improve Clinical Outcomes
21 I Significant Opportunity to Improve Clinical Outcomes Annual cost of treating all antibiotic - resistant infections in the US: $21 - $34 billion 1 Pseudomonas aeruginosa ARMP candidate AP - PA02 Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia ARMP candidate AP - SA02 • 32,600 new c
Slide 22: Strong Global IP Position Through Pending and Issued Patents
22 I Strong Global IP Position Through Pending and Issued Patents 15 Patent Families, Long - Life Patents, Patents Granted in all Major Jurisdictions Expiration dates through 2039 Armata’s patents and applications cover: Therapeutic phage cocktails (Staphylococcus and Pseudomonas) and uses thereof S
Slide 23: Anticipated Topline Milestones 2020/2021
23 I Pseudomonas phage program x Obtained nondilutive funding to partially support clinical studies – Awarded $5 million Therapeutics Development Award through Cystic Fibrosis Foundation • File US IND • Initiate Phase 1b/2 CF study and obtain topline data • Advance into new indication Staphylococcus
Slide 24: Leadership and Board of Directors
24 I Leadership and Board of Directors Diverse Public Company Drug Development Expertise Management Todd R. Patrick CEO Steve Martin CFO Brian Varnum President and CDO Duane Morris VP, Operations Heather Jones VP, Clinical Development Board of Directors Richard Bastiani Chair Joseph M. Patti Odyssea
Slide 25: Funding and Capitalization
25 I Cash Position • Completed a $25 million private placement of common stock and warrants with Innoviva , Inc. (NASDAQ: INVA) in March 2020 – Innoviva is a holding company receiving royalties from GSK; $1.3B market capitalization • Armata has cash through mid - 2021 Capitalization • 18.6 million c
Slide 26: Highlight Summary
26 I Highlight Summary A Leader in Phage Therapeutics Two bacteriophage candidates in clinical development Natural phage discovery and synthetic biology yield robust pipeline Strong partnerships to support phage development: Merck, Cystic Fibrosis Foundation Phage - specific GMP drug manufacturing f
Slide 27: Armata Pharmaceuticals
'~ ARMATA PHARMACEUTICALS PURPOSEFUL @ PRECISE ¢ POWERFUL
Armata Pharmaceuticals — Investor Presentation (April 2020) on 6ix